Acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease

Bibliography

• CUMMINGS JL, VINTERS HV, COLE GM, KHACHATURIAN ZS: Alzheimer's disease. Etiologies, pathophysiology, cognitive reserve, and treatment opportunities. Neurology (1998) 51 (Suppl. 1):S2–S17.
   Google Scholar
• GEULA C: Abnormalities of neural circuitry in Alzheimer's disease. Neurology (1998) 5 1 (Suppl. 1):S18–S29.
   Google Scholar
• GAUTHIER S: Do we have a treatment for Alzheimer'sdisease - yes. Arch. Neurol (1999) 56:738–739.
   PubMed Web of Science ®Google Scholar
• GIACOBINI E: Cholinesterase inhibitors do more than inhibit cholinesterase. In: Alzheimer's disease: From Molecular Biology to Therapy. Becker R, Giacobini E (Eds.), Birkhauser, Boston, USA (1996):187–204.
   Google Scholar
• •An overview of the mode of actions of CI from one of the pioneers in this field.
   Google Scholar
• SUMMERS WK, MAJOVSKI LV, MARSH GM et al.: Oral tetrahydroaminoacridine in long term treatment of senile dementia, Alzheimer type. New Engl. J. Merl. (1986) 315:1241–1245.
   PubMed Web of Science ®Google Scholar
• GAUTHIER S: Update on the diagnostic methods, natural history and outcome variables in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. (1998) 9\(Suppl. 3):2–7.
   Google Scholar
• MCKHANN G, DRACHMAN D, FOLSTEIN M et al: Clinicaldiagnosis of Alzheimer's disease: report of the NINCDS-ADRDA workgroup. Neurology (1 98 4) 34:939–944.
   Google Scholar
• FOLSTEIN MF, FOLSTEIN SE, MCHUGH PR: Mini MentalState: a practical method for grading the cognitive state of patients for the clinician. J. Psychiat. Res. (1975) 12:189–198.
   PubMed Web of Science ®Google Scholar
• SCLAN SG, REISBERG B: Functional Assessment Staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int. Psychogeriatr. (1992) 4\(Suppl. 0:55–69.
   Google Scholar
• BARCLAY LL, ZEMCOV A, BLASS JP, SANSONE J: Survival in Alzheimer's disease and vascular dementia. Neurology (1985) 35:834–840.
   PubMed Web of Science ®Google Scholar
• ROSEN WG, MOHS RC, DAVIS KL: A new rating scale for Alzheimer's disease. Am. J. Psychiat. (1 9 8 4) 141:1356-1364.
   Google Scholar
• SCHNEIDER LS, OLIN JT, DOODY RS et al.: Validity andreliability of the Alzheimer's disease Cooperative Study: Clinical Global Impression of Change. Alzheimer Dis. Assoc. Disord. (1997) 11\(Suppl. 2):S22–S32.
   Google Scholar
• LEBER P: Guidelines for clinical evaluation of antidementia drugs. US Food and Drug Administration, Washington, DC, USA (1990).
   Google Scholar
• •For better or for worse, this discussion paper has driven the way CI have been tested in RCT for the past nine years.
   Google Scholar
• GAUTHIER S, BOUCHARD R, LAMONTAGNE A et al: Tetrahydroaminoacridine-lecithin combination treatment in patients with intermediate-stage Alzheimer's disease. New Engl. J. Med. (1 99 0) 322:1272-1276.
   Google Scholar
• MOLLOY DW, GUYATT GH, WILSON DB, DUKE R, REES L, SINGER J: Effects of tetrahydroaminoacridine on cognition, function and behavior in Alzheimer's disease. Can. Merl. Assoc. J. (1991) 144:29–34.
   PubMed Web of Science ®Google Scholar
• DAVIS KL, THAL LJ, GAMZU ER et al: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New Engl. J. Med. (1 99 2) 327:1253-1259.
   Google Scholar
• FARLOW M, GRACON SI, HERSHEY LA et al.: A controlledtrial of tacrine in Alzheimer's disease. JAMA (1992) 268:2523–2529.
   PubMed Web of Science ®Google Scholar
• KNAP MJ, KNOPMAN DS, SOLOMON PR et al: A 30-weekrandomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA (1994) 2 71 :985–991.
   Google Scholar
• KNOPMAN D, SCHNEIDER L, DAVIS K, THE TACRINE STUDY GROUP: Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology (1996) 47:166–177.
   PubMed Web of Science ®Google Scholar
• POIRIER J, DELISLE MC, QUIRION R et al.: ApolipoproteinE4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc. Natl Acad. Sci. USA (1995) 92:12260–12264.
   PubMed Web of Science ®Google Scholar
• •This article set the stage for the concept of pharmacoge-netics in AD.
   Google Scholar
• FARLOW MR, LAHIRI DK, POIRIER J, DAVIGNON J, SCHNEIDER L, HUI SL: Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology (1998) 50:669–677.
   PubMed Web of Science ®Google Scholar
• SANDS LP, KATZ I, SCHNEIDER L: Assessing individual patients for cognitive benefits from acetylcholines-terase inhibitors. Alzheimer Dis. Assoc. Dis. (1999). (In Press).
   Google Scholar
• QIZILBASH N, WHITEHEAD A, HIGGINS J et al: Cholines-terase inhibition for Alzheimer's disease. A meta-analysis of the tacrine trials. JAMA (1998) 280:1777–1782.
   PubMed Web of Science ®Google Scholar
• •A very challenging meta-analysis of the numerous RCT with tacrine. Needs to be done with all CI to detect more subtle clinical benefits that can be useful to detect clinical effective-ness and to confirm dose-effects relationships.
   Google Scholar
• KAUFER DI, CUMMINGS JL, CHRISTINE D: Effects of tacrine on behavioral symptoms in Alzheimer's disease: an open label study. J. Geriatr. Psychiatry Neurol (1996) 9:1–6.
   PubMed Web of Science ®Google Scholar
• RASKIND MA, SADOVSKY CH, SIGMUND WR, BEITLER PJ, AUSTER SB: Effects of tacrine on language, praxis and concognitive behavioral problems in Alzheimer's disease. Arch. Neurol. (1997) 54:836–840.
   PubMed Web of Science ®Google Scholar
• ROGERS SL, FRIEDHOFF LT, THE DONEPEZIL STUDY GROUP: The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia (1996) 7:293–303.
   PubMedGoogle Scholar
• ROGERS SL, DOODY RS, MOHS RC, FRIEDHOFF LT, THEDONEPEZIL STUDY GROUP: Donepezil improves cognition and global function in Alzheimer's disease. A 15-week, double-blind, placebo-controlled study. Arch. Intern. Med. (1998) 158:1021–1031.
   Google Scholar
• ROGERS SL, FARLOW MR, DOODY RS, MOHS R, FRIEDHOFF LT, THE DONEPEZIL STUDY GROUP: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology (1998) 50:136–145.
   PubMed Web of Science ®Google Scholar
• BURNS A, ROSSOR M, HECKER J et al.: The effects ofdonepezil in Alzheimer's disease - results from a multinational trial. Dement. Geriatr. Cogn. Disord (1999) 10:237–244.
   PubMed Web of Science ®Google Scholar
• TEUNISSE S, DERIX M, VAN CREVEL H: Assessing theseverity of dementia, patient and caregiver. Arch. Neurol (1991) 48:274–277.
   PubMed Web of Science ®Google Scholar
• MORRIS JC: The clinical dementia rating (CDR): currentversion and scoring rules. Neurology (1 9 9 3) 43:2412-2413.
   Google Scholar
• •The instrument that could prove to be the most useful in RCT for demonstration of slowing of disease progression, and can be used in clinical practice for monitoring response to treatment with CI for extended periods.
   Google Scholar
• ROGERS SL, FRIEDHOFF LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur. Neuropsy-chopharmacol (1998) 8:67–75.
   PubMed Web of Science ®Google Scholar
• •The first evidence for a sustained symptomatic benefit beyond the six-months duration of most RCT in AD.
   Google Scholar
• DOODY RS: Clinical profile of donepezil in thetreatment of Alzheimer's disease. Gerontology (1999) 45 (Suppl. 0:23–32.
   Google Scholar
• ANAND R, GHARABAWI G, ENZ A: Efficacy and safetyresults of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J. Drug Clin. Pract. (1996) 8: 1–8.
   Google Scholar
• COREY-BLOOM J, ANAND R, VEACH J FOR THE ENA 713B352 STUDY GROUP: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int. J. Geriat. Psychopharmacol. (1998) 1:55–65.
   Google Scholar
• ROSLER M, ANAND R, CICIN-SAIN A et al.: Efficacy andsafety of rivastigmine in patients with Alzheimer's disease: results of an international, 26-week, multicentre, randomised, placebo-controlled trial. Br. Med. J. (1999) 318:633-638. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(10)
   Google Scholar
• DEJONG R, OSTERLUND 0, ROY G: Measurement of quality-of-life changes in patients with Alzheimer's disease. Clin. Ther. (1989) 1:545–554.
   Google Scholar
• SCHNEIDER LS, ANAND R, FARLOW MR: Systematic review of the efficacy of rivastigmine for patients with Alzheimer's disease. Int. J. Geriatric Psychopharmacol (1998) 1 (Suppl. 1):S26–S34.
   Google Scholar
• SCHMIDT BH, HEINIG R: The pharmacological basis formetrifonate's favourable tolerability in the treatment of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. (1998) 9\(Suppl. 2):15–19.
   Google Scholar
• CUMMINGS JL, CYRUS PA, BIEBER F et al.: Metrifonatetreatment of the cognitive deficits of Alzheimer's disease. Neurology (1998) 50:1214–1221.
   PubMed Web of Science ®Google Scholar
• MORRIS JC, CYRUS PA, ORAZEM J et al.: Metrifonatebenefits cognitive, behavioral and global function in patients with Alzheimer's disease. Neurology (1998) 50:1222–1230.
   PubMed Web of Science ®Google Scholar
• CYRUS PA, RUZICKA BB, GULANSKI B: The dose-relatedimprovement by metrifonate of the cognitive performance of Alzheimer's disease patients. Neurology (1998) 50:A89.
   Web of Science ®Google Scholar
• GELINAS I, GAUTHIER S, CYRUS PA, RUZICKA BB,GULANSKI B: The efficacy of metrifonate in enhancing the ability of Alzheimer's disease patients to perform basic and instrumental activities of daily living. Neurology (1998) 50:A91.
   Web of Science ®Google Scholar
• GELINAS I, GAUTHIER L, MCINTYRE M, GAUTHIER S:Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am. J. Occup. Ther. (1999). (In Press).
   Google Scholar
• CUMMINGS JL, MEGA M, GRAY K, ROSENBERG-THOMPSON S, CARUSI DA, GORNBEIN J: The Neuropsy-chiatric Inventory: comprehensive assessment of psychopathology of dementia. Neurology (1994) 44: 2308–2314.
   PubMed Web of Science ®Google Scholar
• CUMMINGS JL, CYRUS PA, RUZICKA BB, GULANSKI B:The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer's disease. Neurology (1998) 50:A251.
   Web of Science ®Google Scholar
• FARLOW MR, LAHIRI DK, BRASHEAR A, CYRUS PA, GULANSKI B: Metrifonate in the symptomatic treatment of Alzheimer's disease: influence of apolipo-protein E genotype. Neurology (1998) 50:A88.
   PubMed Web of Science ®Google Scholar
• PONTECORVO MJ: Clinical development of galantamine: evaluation of a compound with possible acetylcholinesterase inhibiting and nicotinic modula-tory activity. Neurobiol. Aging (1998) 19:57.
   PubMed Web of Science ®Google Scholar
• WILCOCK G, WILKINSON D: Galantamine hydrobro-mide: interim results of a group comparative, placebo-controlled study of efficacy and safety in patients with a diagnosis of senile dementia of the Alzheimer type. In: Alzheimer's Disease: Biology, Diagnosis and Therapeutics. Iqbal K, Winblad B, Nishimura T, Takeda M, Wisniewski HM (Eds.), John Wiley & Sons, Chichester, UK (1997):661–664.
   Google Scholar
• MACGOWAN SH, WILCOCK GK, SCOTT M: Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int. GeriaL PsychiaL (1998) 13:625–630.
   PubMed Web of Science ®Google Scholar
• HILLS, MCGETTIGAN P: Drug authorities' policy on theassessment of drugs for dementia. In: Health Economics of Dementia. Wimo A, Jänsson B, Karlsson G, Winblad B (Eds.) John Wiley & Sons, Chichester, UK (1998):435–450.
   Google Scholar
• MAX W: Cost of illness of dementia. In: Health Economics of Dementia. Wimo A, Jänsson B, Karlsson G, Winblad B (Eds.), John Wiley & Sons, Chichester, UK (1998):197–206.
   Google Scholar
• HUX MJ, O'BRIEN B, ISKEDJIAN M, GOEREE R, GAGNON M, GAUTHIER S: Relation between severity of Alzheimer's disease and costs of caring. Can. Med. Assoc. J. (1998) 159:457–465.
   Google Scholar
• SMALL GW, DONOHUE JA, BROOKS RL: An economic evaluation of donepezil in the treatment of Alzheimer's disease. Clin. Ther. (1998) 20:838–850.
   PubMed Web of Science ®Google Scholar
• NEWMANN PJ, HERMANN RC, KUNTZ KM et al.: Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology (1999) 52:1138–1145.
   PubMed Web of Science ®Google Scholar
• STEWART A, PHILLIPS R, DEMPSEY G: Pharmacotherapy for people with Alzheimer's disease: a Markov-cycle evaluation of five years' therapy using donepezil. Int. J. GeriaL PsychiaL (1998) 13:445–453.
   PubMed Web of Science ®Google Scholar
• O'BRIEN BJ, GOEREE R, HUX M et al.: Economic evalua-tion of donepezil for the treatment of Alzheimer's disease in Canada. JAGS (1999) 47:570–578.
   Google Scholar
• LUBECK DP, MAZONSON PD, BOWE T: Potential effect of tacrine on expenditures for Alzheimer's disease. Med. Interface (1994) 7:130–138.
   PubMedGoogle Scholar
• WIMO A, KARLSSON G, NORDBERG A, WINBLAD B: Treatment of Alzheimer's disease with tacrine: a cost-analysis model. Alzheimer Dis. Assoc. Disord. (1997) 4:191–200.
   Google Scholar
• WHITEHOUSE P, WINBLAD B, SHOSTAK D et al.: First International Pharmacoeconomic Conference on Alzheimer's disease: report and summary. Alzheimer Dis. Assoc. Dis. (1998) 12:266–280.
   PubMed Web of Science ®Google Scholar
• •The first conference dedicated to the phamacoeconomics of dementia. Next meeting in Stockholm, 2002.
   Google Scholar
• WINBLAD B, KARLSSON G, JONSSON B, WIMO A: A proposed health economics research agenda for dementia. In: Health Economics of Dementia. Wimo A, Jänsson B, Karlsson G, Winblad B (Eds.), John Wiley & Sons, Chichester, UK (1998):563–565.
   Google Scholar
• KNOPMAN D, KAHN J, MILES S: Clinical research designs for emerging treatments for Alzheimer's disease. Arch. Neurol. (1998) 55:1425–1429.
   PubMed Web of Science ®Google Scholar
• KNAPP M, WILKINSON D, WIGGLESWORTH R: The economic consequences of Alzheimer's disease in the context of new drug development. Int. J. GeriaL PsychiaL (1998) 13:531–543.
   PubMed Web of Science ®Google Scholar
• GAUTHIER S: Managing expectations in the long-term treatment of Alzheimer's disease. Gerontology (1999) 45 (Suppl. 1):33–38. © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1999) 8(10)
   Google Scholar
• LOVESTONE S, GRAHASM N, HOWARD R: Guidelines on drug treatment for Alzheimer's disease. Lancet (1997) 550:232–233.
   Web of Science ®Google Scholar
• HARVEY RJ: A review and commentary on a sample of 15 UK guidelines for the drug treatment of Alzheimer's disease. Int. J. Geriat. Psychiat. (1999) 14:249–256.
   PubMed Web of Science ®Google Scholar
• RABINS P, BLACKER D, BLAND W et al.: Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias of late-life. Am. J. Psychiat. (1997) 154 (Suppl.):1–39.
   Google Scholar
• SMALL GW, RABINS PV, BARRY PP et al: Diagnosis and treatment of Alzheimer's disease and related disorders. JAMA (1997) 278:1363–1371.
   PubMed Web of Science ®Google Scholar
• PATTERSON C, GAUTHIER S, BERGMAN H et al.: The recognition, assessment and management of dementing disorders: conclusions from the Canadian consensus conference on dementia. Can. Med. Assoc. J. (1999) 160\(Suppl. 12):S1–520.
   Google Scholar
• BRODATY H: The family and drug treatments for Alzheimer's disease. In: Pharmacotherapy of Alzheimer's Disease. Gauthier S (Ed.), Martin Dunitz, London, UK (1998):123–139.
   Google Scholar
• ••The very important perspective of the patient and caregiversin what they expect from CI therapy.
   Google Scholar
• CUTLER NR, SRAMEK JJ: Tolerability profiles of AChEIs: a critical component of care for Alzheimer's disease patients. Int. J. Geriat. Psychopharmacol (1998) 1 (Suppl. 1):S20–S25.
   Google Scholar
• KNOPMAN DS, MORRIS JC: An update on primary drug therapies for Alzheimer's disease. Arch. Neurol (1997) 54:1406–1140.
   PubMed Web of Science ®Google Scholar
• •A very good overview of the field.
   Google Scholar
• GIACOBINI E: Cholinesterase inhibitors for Alzheimer's disease therapy: pharmacokinetic and pharmacodynamic considerations. In: Pharmaco-therapy of Alzheimer's Disease. Gauthier S (Ed.), Martin Dunitz, London, UK (1998):75–92.
   Google Scholar
• ROCKWOOD K, STOOLE P, HOWARD K, MALLERY L: Use of goal attainment scaling to measure treatment effects in an anti-dementia drug trial. Neuropepidemiology (1996) 15:330–338.
   PubMed Web of Science ®Google Scholar
• ALBERT SM, SANO M, MARDER K et al: Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology (1997) 49:38–43.
   PubMed Web of Science ®Google Scholar
• POST SG: Societal and ethical considerations. In:Pharmacotherapy of Alzheimer's Disease. Gauthier S (Ed.) Martin Dunitz, London, UK (1998):113–122.
   Google Scholar
• KARLAWISH JHT, WHITEHOUSE P: Is the placebo control obsolete in a world after donepezil and vitamin E? Arch. Neurol (1998) 55:1420–1424.
   Web of Science ®Google Scholar
• MURALI DORAISWAM P, STEFFENS DC: Combination therapy for early Alzheimer's disease: what are we waiting for? JAGS (1998) 46:1322–1324.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER LS, FARLOW MR, HENDERSON VW, POGODA JM: Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology (1996) 46:1580–1584.
   PubMed Web of Science ®Google Scholar
• RELKIN N, ORAZEM J, MCRAE T: The effect of concomi-tant donepezil and estrogen treatment on the cognitive performance of women with Alzheimer's disease. Neurology (1999) 52 (Suppl. 2):A397–A398.
   Google Scholar
• SANO M, ERNESTO C, THOMAS RG et al.: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New Engl. J. Med. (1997) 326:1245–1247.
   Google Scholar
• ••The first RCT in AD using the time to reach milestones'design. A landmark study.
   Google Scholar
• MCCORMICK WC, ABRASS IB: Shifting thinking about memory impairment. Lancet (1998) 352 (Suppl.
   Google Scholar
• PASINETTI GM: Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. J. Neurosci. Res. (1998) 54:1–6.
   PubMed Web of Science ®Google Scholar
• MITTELMAN MS, FERRIS SH, SHULMAN E, STEINBERG G,LEVIN B: A family intervention to delay nursing home placement of patients with Alzheimer's disease. JAMA (1996) 276:1725–1731.
   PubMed Web of Science ®Google Scholar
• •The most quoted study on the value of non-pharmacologic interventions in AD.
   Google Scholar
• WENGEL SP, ROCCAFORTE WH, BURKE WJ: Donepezil improves symptoms of delirium in dementia: implica-tions for future research. J. Geriatr. Psychiat. Neurol (1998) 11:159–161.
   PubMed Web of Science ®Google Scholar
• AARSLAN D, BRONNICK K, KARLSEN K: Donepezil for Dementia with Lewy Bodies: a case study. Int. j Geriat. Psychiat. (1999) 14:69–74.
   PubMed Web of Science ®Google Scholar
• GAUTHIER S: Clinical trials and therapy. Curr. Opin. Neurol. (1998) 11:435–438.
   PubMed Web of Science ®Google Scholar
• FARLOW MR: New treatments in Alzheimer's disease and the continued need for placebo-controlled trials. Arch. Neurol (1998) 55:1396–1398.
   PubMed Web of Science ®Google Scholar
• ••A broad perspective on the future of RCT in AD, taking intoaccount the perspectives of patients, caregivers, clinicians, regulators, payers and ethicists.
   Google Scholar